

Wolfgang F Richter

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6269088/wolfgang-f-richter-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30 papers	1,272 citations	17 h-index	35 g-index
36 ext. papers	1,573 ext. citations	5.3 avg, IF	4.53 L-index

#	Paper	IF	Citations
30	Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting. <i>MAbs</i> , 2021 , 13, 1938796	6.6	2
29	Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use. <i>International Journal of Toxicology</i> , 2021 , 40, 270-284	2.4	2
28	Novel In Vivo and In Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.. <i>Journal of Pharmaceutical Sciences</i> , 2021 ,	3.9	2
27	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. <i>Nature Communications</i> , 2020 , 11, 3196	17.4	17
26	Heparin chromatography as an predictor for antibody clearance rate through pinocytosis. <i>MAbs</i> , 2020 , 12, 1683432	6.6	24
25	Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans. <i>AAPS Journal</i> , 2020 , 22, 63	3.7	3
24	High-Throughput, Sensitive LC-MS Quantification of Biotherapeutics and Biomarkers Using Antibody-Free, Peptide-Level, Multiple-Mechanism Enrichment via Strategic Regulation of pH and Ionic and Solvent Strengths. <i>Analytical Chemistry</i> , 2019 , 91, 3475-3483	7.8	5
23	Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 1443-1456	4	20
22	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2018 , 24, 4785-4797	12.9	84
21	Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. <i>BioDrugs</i> , 2018 , 32, 425-440	7.9	131
20	Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. <i>MAbs</i> , 2018 , 10, 803-813	6.6	17
19	Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 2017 , 106, 2853-2859	3.9	21
18	Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice. <i>Reproductive Toxicology</i> , 2017 , 73, 362-371	3.4	4
17	In Vivo Biotransformation of the Fusion Protein Tetranectin-Apolipoprotein A1 Analyzed by Ligand-Binding Mass Spectrometry Combined with Quantitation by ELISA. <i>Analytical Chemistry</i> , 2016 , 88, 11670-11677	7.8	14
16	Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice. <i>AAPS Journal</i> , 2016 , 18, 354-61	3.7	3
15	Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion Protein. <i>Toxicological Sciences</i> , 2016 , 150, 378-89	4.4	8
14	Subcutaneous absorption of biotherapeutics: knowns and unknowns. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1881-9	4	125

13	6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 9874-96	8.3	24
12	The effects of interleukin-6 signal blockade on immune system, reproductive and skeletal development in juvenile mice. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2013 , 98, 170-82		5
11	Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. <i>PLoS ONE</i> , 2013 , 8, e80533	3.7	27
10	Mechanistic determinants of biotherapeutics absorption following SC administration. <i>AAPS Journal</i> , 2012 , 14, 559-70	3.7	193
9	Gantenerumab: a novel human anti-A β antibody demonstrates sustained cerebral amyloid- β binding and elicits cell-mediated removal of human amyloid- β <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 49-69	4.3	252
8	Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. <i>MAbs</i> , 2012 , 4, 243-55	6.6	83
7	Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011 , 38, 581-93	2.7	3
6	Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2007 , 42, 900-9	2.2	96
5	The distribution pattern of radioactivity across different tissues in quantitative whole-body autoradiography (QWBA) studies. <i>European Journal of Pharmaceutical Sciences</i> , 2006 , 28, 155-65	5.1	17
4	Design of experiment (DOE) methods maximize information from a minimal number of animals in special cases of preclinical bioavailability testing. <i>Pharmaceutical Development and Technology</i> , 2003 , 8, 453-8	3.4	3
3	Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. <i>Journal of Pharmaceutical Sciences</i> , 1998 , 87, 496-500	3.9	17
2	Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. <i>Journal of Pharmaceutical Sciences</i> , 1995 , 84, 1285-90	3.9	31
1	Immunogenicity: Its Impact on ADME of Therapeutic Biologics1-12		2